{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:52:40Z","timestamp":1791568360069,"version":"4.3.4"},"reference-count":23,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"unspecified","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Ministry of Health of the Czech Republic","award":["IN 00023001"],"award-info":[{"award-number":["IN 00023001"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,9,18]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"\n Objectives<\/jats:title>\n To determine the prevalence of chronic kidney disease (CKD) in internal medicine outpatients in a Central European tertiary care setting, identify associated risk factors and assess use and potential impact of renoprotective therapies. We hypothesised that CKD is common, underdiagnosed and undertreated.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Cross-sectional observational study.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Tertiary care outpatient clinics in Central Europe.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n 1933 adult outpatients at risk for CKD were screened; an expanded cohort of 2903 patients with available laboratory data was included for secondary analyses. Inclusion required assessment of estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (uACR) within the study period. Kidney transplant recipients were excluded.<\/jats:p>\n <\/jats:sec>\n \n Primary and secondary outcome measures<\/jats:title>\n The primary outcome was CKD prevalence defined by eGFR and uACR per kidney disease improving global outcomes criteria. Secondary outcomes included detection of previously unrecognised CKD, associations with clinical risk factors and prescription rates of renoprotective therapies. CKD prevalence was also assessed using age-calibrated eGFR thresholds. An exploratory outcome was model-projected gain in dialysis-free time with treatment initiation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n CKD prevalence was 32.5% (95% credible interval (CrI) 30.5 to 34.6)\u2009and remained high after age-calibrated eGFR adjustment. One new case was revealed for every 5.2 patients screened. CKD odds increased with age (per 25 years: OR 3.81, 95% CrI 3.09 to 4.67), non-renal transplantation (OR 4.38, 95% CrI 3.30 to 5.84), hypertension (OR 2.61, 95% CrI 1.96 to 3.54), heart failure or atrial fibrillation (OR 1.59, 95% CrI 1.29 to 1.96), type 1 (OR 1.97, 95% CrI 1.47 to 2.63)\u2009and type 2 diabetes (OR 1.46, 95% CrI 1.21 to 1.77), and atherosclerotic disease (OR 1.49, 95% CrI 1.20 to 1.82). Renoprotective therapy use was suboptimal (sodium-glucose co-transporter-2 inhibitors 42%, glucagon-like peptide-1 receptor agonists 41.7%, nonsteroidal mineralocorticoid receptor antagonists 6.7% of eligible patients). The model-projected gain in dialysis-free time by initiation of renoprotective treatment was estimated to be 11.13 months per CKDe patient on average.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n CKD is highly prevalent in tertiary care outpatients and efficiently detected through targeted screening. Suboptimal use of renoprotective therapies highlights a major treatment gap. Further research should address implementation strategies.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n NCT07153432<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-121190","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:09:08Z","timestamp":1791565748000},"page":"e121190","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence, risk factors and renoprotective treatment of chronic kidney disease among internal medicine outpatients at a Central European tertiary care centre: a cross-sectional study"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct07153432","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct07153432","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ivan","family":"Zahradka","sequence":"first","affiliation":[{"name":"Department of Nephrology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vojtech","family":"Petr","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Tichanek","sequence":"additional","affiliation":[{"name":"Department of Data Science, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Chroma","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Neskudla","sequence":"additional","affiliation":[{"name":"Department of Data Science, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kahle","sequence":"additional","affiliation":[{"name":"Department of Data Science, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bem","sequence":"additional","affiliation":[{"name":"Diabetes Centre, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Trunecka","sequence":"additional","affiliation":[{"name":"Department of Hepatogastroenterology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Adamkova","sequence":"additional","affiliation":[{"name":"Centre of Preventive Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Hruba","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Hlavac","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Public Health, University of Ostrava, Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1049-2195","authenticated-orcid":false,"given":"Ondrej","family":"Viklicky","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Institute of Clinical and Experimental Medicine, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2026100606201704000_16.10.e121190.1","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-00961-5"},{"key":"2026100606201704000_16.10.e121190.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31694-5"},{"key":"2026100606201704000_16.10.e121190.3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","article-title":"EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors","volume":"16","author":"Fern\u00e1ndez-Fernandez","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026100606201704000_16.10.e121190.4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-067386","article-title":"Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study","volume":"13","author":"Tangri","year":"2023","journal-title":"BMJ Open"},{"key":"2026100606201704000_16.10.e121190.5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101347","article-title":"A call for urgent action on chronic kidney disease across Europe","volume":"54","author":"Ferro","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026100606201704000_16.10.e121190.6","unstructured":"Viklick\u00fd O , Rychl\u00edk I , Pr\u00e1zn\u00fd M , et al . Doporu\u010den\u00fd postup \u010cesk\u00e9 nefrologick\u00e9 spole\u010dnosti pro diagnostiku a l\u00e9\u010dbu chronick\u00e9ho onemocn\u011bn\u00ed ledvin (CKD) u praktick\u00fdch l\u00e9ka\u0159\u016f. 2024."},{"key":"2026100606201704000_16.10.e121190.7","unstructured":"World Health Organization . International classification of diseases tenth revision (ICD-10). 6th edn. Geneva: World Health Organization, 2019."},{"key":"2026100606201704000_16.10.e121190.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2102953\/SUPPL_FILE\/NEJMOA2102953_DISCLOSURES.PDF"},{"key":"2026100606201704000_16.10.e121190.9","doi-asserted-by":"publisher","DOI":"10.1016\/J.KINT.2023.10.018"},{"key":"2026100606201704000_16.10.e121190.10","first-page":"17","article-title":"An Age-Calibrated Definition of Chronic Kidney Disease: Rationale and Benefits","volume":"37","author":"Delanaye","year":"2016","journal-title":"Clin Biochem Rev"},{"key":"2026100606201704000_16.10.e121190.11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1017\/rsm.2025.2","article-title":"Effect modification and non-collapsibility together may lead to conflicting treatment decisions: A review of marginal and conditional estimands and recommendations for decision-making","volume":"16","author":"Phillippo","year":"2025","journal-title":"Res Synth Methods"},{"key":"2026100606201704000_16.10.e121190.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"2026100606201704000_16.10.e121190.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"2026100606201704000_16.10.e121190.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"2026100606201704000_16.10.e121190.15","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/S0735-1097(24)03898-1","article-title":"Effects of sglt2 inhibitors on cardiovascular outcomes with and without baseline use of glp-1 receptor agonists: A smart-c collaborative meta-analysis","volume":"83","author":"Neuen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026100606201704000_16.10.e121190.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-089783","article-title":"Rate of decline in kidney function with age: a systematic review","volume":"14","author":"Guppy","year":"2024","journal-title":"BMJ Open"},{"key":"2026100606201704000_16.10.e121190.17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5049\/EBP.2024.22.2.21","article-title":"A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond","volume":"22","author":"Han","year":"2024","journal-title":"Electrolyte Blood Press"},{"key":"2026100606201704000_16.10.e121190.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-025-04028-z","article-title":"The global, regional, and national patterns of change in the burden of chronic kidney disease from 1990 to 2021","volume":"26","author":"Guo","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026100606201704000_16.10.e121190.19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/ckj\/sfaa218","article-title":"A roadmap for optimizing chronic kidney disease patient care and patient-oriented research in the Eastern European nephrology community","volume":"14","author":"Sever","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026100606201704000_16.10.e121190.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60687-X"},{"key":"2026100606201704000_16.10.e121190.21","first-page":"248","article-title":"Internal medicine and the holistic approach to the patient between globalization and advanced technologies","volume":"103","author":"Dammacco","year":"2012","journal-title":"Recenti Prog Med"},{"key":"2026100606201704000_16.10.e121190.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021744"},{"key":"2026100606201704000_16.10.e121190.23","doi-asserted-by":"crossref","unstructured":"De Keyzer ELR , Herder F , B\u00f6hne A , et al . Ancient and Recent Riverine Gene Flow Contributed to the Adaptive Radiation of Sailfin Silversides in Wallace\u2019s Dreampond. Mol Ecol 2026.:e70414. doi:10.5281\/zenodo.18390299","DOI":"10.1101\/2025.04.16.648611"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-121190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:09:12Z","timestamp":1791565752000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-121190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,6]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bmjopen-2026-121190"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-121190","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}